Companies /Healthcare

Lantheus Holdings Inc

NASDAQ: LNTH Drug Manufacturers - Specialty & Generic
$100.25
▼ $0.14 (−0.14%) today
Markets closed · 6:14pm ET

Q3 2025 Earnings

Reported Nov 6, 2025, 7:39am ET · SEC source
$1.27
Beat +0.24%
EPS · est. $1.27
$384.0M
Beat +5.37%
Revenue · est. $364.5M
+11.5%
Beating market
LNTH vs S&P since report
4 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−18%−12%−6%0Nov 6Nov 7report 7:39am ETearnings−1.9%−17.2%
−18%−12%−6%0Nov 6Nov 7earnings−1.9%−17.2%
LNTH −17.2%S&P 500 −1.9%
−18%−12%−6%0Nov 6Nov 7report 7:39am ETearnings−3.3%−17.2%
−18%−12%−6%0Nov 6Nov 7earnings−3.3%−17.2%
LNTH −17.2%NASDAQ −3.3%
−18%−12%−6%0Nov 5Nov 13report 7:39am ETearnings−1.0%−14.3%
−18%−12%−6%0Nov 5Nov 13earnings−1.0%−14.3%
LNTH −14.3%S&P 500 −1.0%
−18%−12%−6%0Nov 5Nov 13report 7:39am ETearnings−2.6%−14.3%
−18%−12%−6%0Nov 5Nov 13earnings−2.6%−14.3%
LNTH −14.3%NASDAQ −2.6%
−6.19%
Day of report
−4.88%
Next session
−1.06%
One week
+13.39%
30 days

S&P 500 over the same 30 days: +1.90%.

Did LNTH Beat Earnings? Q3 2025 Results

Lantheus posted a solid beat on both the top and bottom lines in Q3 2025, delivering revenue of $384.01 million against a consensus estimate of $364.46 million, a 5.37% positive surprise, while adjusted diluted EPS of $1.27 edged past the $1.27 consensus by 0.24%, though revenue grew just 1.4% year over year as the company navigated a complex integration period. The primary story beneath the headline numbers was the weight of the Life Molecular Imaging acquisition, which closed in July and effectively doubled both R&D and G&A expenses, compressing adjusted operating margin to 31.1% from 43.6% a year ago. Flagship PSMA agent PYLARIFY slid 7.4% to $240.62 million, a headwind compounded by ongoing securities fraud litigation alleging the company misled investors about Pylarify's competitive dynamics earlier in 2025. Looking ahead, Lantheus narrowed its full-year revenue guidance to $1.49 billion to $1.51 billion and adjusted EPS to $5.50 to $5.65, with three PDUFA dates on the horizon that could meaningfully reshape its product portfolio through 2026.

Key Takeaways
  • PYLARIFY remains largest revenue contributor but declined 7.4% YoY
  • DEFINITY grew 6.3% driven by continued market penetration
  • Life Molecular Imaging acquisition contributed Neuraceq revenue of $20.4 million with no prior-year comparable
  • Total precision diagnostics grew 25.0% driven by Neuraceq addition and DEFINITY growth
  • Significant increase in acquisition, integration and divestiture-related costs of $35.0 million in Q3 2025
  • R&D spending nearly doubled to $48.0 million reflecting Life Molecular Imaging integration

“Lantheus' third quarter results underscore the strength of our strategy and the dedication of our team as we continue to advance our leadership in radiopharmaceuticals.”

Lantheus CEO, on the earnings call

Forward Guidance & Outlook

Lantheus updated its FY 2025 guidance: revenue of $1.49 billion to $1.51 billion (narrowed from prior $1.475 billion to $1.51 billion) and adjusted fully diluted EPS of $5.50 to $5.65 (narrowed from prior $5.50 to $5.70), reflecting the Life Molecular Imaging acquisition and current business outlook. The company has three upcoming PDUFA dates: new PSMA PET formulation (March 6, 2026), LNTH-2501 for neuroendocrine tumors (March 29, 2026), and MK-6240 for Alzheimer's disease (August 13, 2026). The company plans to divest its SPECT business to SHINE Technologies.

LNTH YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$200.0M$400.0M$378.7M$384.0MRevenue$242.1M$222.4MGross Profit$133.7M$43.6MOperating Income$131.1M$27.8MNet Income
$0$200.0M$400.0MRevenueGross ProfitOperating IncomeNet Income

LNTH Revenue by Segment

PYLARIFY$240.6M−7.4%
DEFINITY$81.8M+6.3%
Neuraceq$20.4M+100.0%
TechneLite$21.1M+3.2%
Strategic partnerships and other revenue$13.7M−10.1%
Strategic partnerships and other
Other precision diagnostics$6.3M+0.9%

Figures from SEC filings and company reports. Not investment advice.